Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 9100622)

1.

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM.

Lancet. 1997 Apr 5;349(9057):971-7.

PMID:
9100622
2.

Augmenting outcomes in patients with advanced heart failure.

Felker GM.

Eur Heart J. 2015 Jun 20. pii: ehv283. [Epub ahead of print] No abstract available.

PMID:
26093637
3.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators.

Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].

PMID:
20801500
4.

Pigmented deposits on a Boston keratoprosthesis from topical ibopamine.

Kanoff JM, Colby K.

Cornea. 2010 Sep;29(9):1069-71. doi: 10.1097/ICO.0b013e3181d07567.

PMID:
20567201
5.

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G.

Lancet. 2008 Oct 4;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8. Epub 2008 Aug 29.

PMID:
18757090
6.

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G.

Lancet. 2008 Oct 4;372(9645):1231-9. doi: 10.1016/S0140-6736(08)61240-4. Epub 2008 Aug 29.

PMID:
18757089
7.

Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients.

Petrie CJ, Voors AA, van Veldhuisen DJ.

Int J Cardiol. 2009 Jan 24;131(3):336-44. doi: 10.1016/j.ijcard.2007.10.023. Epub 2008 Jan 14.

PMID:
18192039
8.

Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma.

Ugahary LC, Ganteris E, Veckeneer M, Cohen AC, Jansen J, Mulder PG, van Meurs JC.

Am J Ophthalmol. 2006 Mar;141(3):571-3.

PMID:
16490513
9.

Confounding by contraindication in a nationwide cohort study of risk for death in patients taking ibopamine.

Feenstra H, Grobbee RE, in't Veld BA, Stricker BH.

Ann Intern Med. 2001 Apr 3;134(7):569-72.

PMID:
11281739
10.

Achieving appropriate endpoints in heart failure trials: the PRIME-II protocol. The Second Perspective Randomised study of Ibopamine on Mortality and Efficacy.

Hampton JR, Van Veldhuisen DJ, Cowley AJ, Kleber FX, Charlesworth A.

Eur J Heart Fail. 1999 Mar;1(1):89-93.

PMID:
10937985
11.

Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ.

Circulation. 2000 Jul 11;102(2):203-10.

12.

Dopamine in heart failure and critical care.

Smit AJ.

Clin Exp Hypertens. 2000 Apr;22(3):269-76. Review.

PMID:
10803732
13.

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.

N Engl J Med. 1999 Sep 2;341(10):709-17.

15.

[Risk factors for dying among ibopamine users].

de Graeff PA, Elferink AJ, Lekkerkerker JF.

Ned Tijdschr Geneeskd. 1999 May 22;143(21):1114-5. Dutch. No abstract available.

PMID:
10368748
16.

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

[No authors listed]

Lancet. 1999 Jan 2;353(9146):9-13.

PMID:
10023943
17.

Risk factors for mortality in users of ibopamine.

Feenstra J, in't Veld BA, van der Linden PD, Grobbee DE, Stricker BH.

Br J Clin Pharmacol. 1998 Jul;46(1):71-7.

18.

Evaluation of ibopamine plus prazosin in congestive heart failure.

Naidoo DP, Rocke A, Mitha AS.

S Afr Med J. 1998 Feb;88 Suppl 1:C25-31.

PMID:
9542492
19.

A nested case-control study on mortality in users of ibopamine.

Stricker BH, Feenstra J, Ottervanger JP, Porsius AJ, Grobbee DE.

Neth J Med. 1997 Nov;51(5):163-8.

PMID:
9455095
20.

Comparison of captopril and ibopamine in mild to moderate heart failure.

Dohmen HJ, Dunselman PH, Poole-Wilson PA.

Heart. 1997 Sep;78(3):285-90.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk